Yinghui Guan

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Molecular subtypes of hepatocellular carcinoma linked to liver cell lineages and clinical outcomes of combination immunotherapy

  Cell Reports Medicine · 2025-11-28 · 5 citations

• Abstract A023: Erythropoietin (EPO) is a Pharmacodynamic Biomarker for Systemic HIF-2α Inhibition that Correlates with the Clinical Activity of Casdatifan

  Molecular Cancer Therapeutics · 2025-10-22 · 1 citations

• 2Combination casdatifan plus cabozantinib in previously treated patients with clear cell renal cell carcinoma: results from an expansion cohort of ARC-20 (NCT05536141)

  The Oncologist · 2025-10-01

• Translocation of SIRT6 promotes glycolysis reprogramming to exacerbate diabetic angiopathy

  Redox Biology · 2025-06-24 · 3 citations

• Combination casdatifan plus cabozantinib expansion cohort of phase 1 ARC-20 study in previously treated patients with clear cell renal cell carcinoma.

  Journal of Clinical Oncology · 2025-05-28 · 6 citations

• Development and validation of prognostic models based on cell cycle-related signatures for predicting the prognosis of patients with lung adenocarcinoma

  Translational Cancer Research · 2025-05-01

• [The effectiveness of CT-MRI image fusion technology in the preoperative assessment of middle ear cholesteatoma].

  PubMed · 2024-12-24

• PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers

  British Journal of Cancer · 2024-07-06 · 24 citations